Open AccessComparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial
Author(s) -
Paul M. Ridker,
Jean MacFadyen,
Robert J. Glynn,
Gary Bradwin,
Ahmed Hasan,
Nader Rifai
Publication year - 2020
Publication title -
european heart journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.336
H-Index - 293
eISSN - 1522-9645
pISSN - 0195-668X
DOI - 10.1093/eurheartj/ehaa160
Subject(s) - medicine , hazard ratio , myocardial infarction , c reactive protein , acute coronary syndrome , cardiology , coronary artery disease , confidence interval , gastroenterology , inflammation
In epidemiologic cohorts initiated >30 years ago, inflammatory biomarkers, such as interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) were shown to independently predict future cardiovascular events with a magnitude of effect comparable to that of low-density lipoprotein cholesterol (LDLC). Whether aggressive contemporary therapy for atherosclerosis has altered these relationships is unknown yet has major implications for future drug development.